Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540146 | 0.84 | CHEK1 (0.43) | CHEK1ZAP70JAK2ROCK2RPS6KA3 | |
| SCHEMBL1159618 | 0.84 | JAK2 (0.49) | CHEK1ZAP70JAK2ROCK2 | |
| SCHEMBL1159567 | 0.84 | JAK2 (0.48) | CHEK1ZAP70JAK2ROCK2 | |
| SCHEMBL13753079 | 0.83 | JAK2 (0.39) | CHEK1ZAP70JAK2RPS6KA3MELK | |
| SCHEMBL12794862 | 0.80 | ESR1 (0.38) | CHEK1ZAP70JAK2ROCK2 | |
| SCHEMBL15760939 | 0.79 | ZAP70 (0.40) | CHEK1ZAP70JAK2RPS6KA3MELK | |
| SCHEMBL12848802 | 0.79 | CHEK1 (0.46) | CHEK1JAK2ROCK2RPS6KA3MELK | |
| SCHEMBL1159415 | 0.78 | CHEK1 (0.38) | CHEK1ZAP70JAK2ROCK2 | |
| SCHEMBL1050400 | 0.78 | CHEK1 (0.49) | CHEK1JAK2ROCK2RPS6KA3MELK | |
| SCHEMBL30381452 | 0.78 | CHEK1 (0.49) | CHEK1JAK2ROCK2RPS6KA3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | CHEK1 330/4885ZAP70 710/4885JAK2 104/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | CHEK1 368/4885ZAP70 403/4885JAK2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.